A dual ADAM17/MMP inhibitor, compound 16 (TMI-1), demonstrated superior in vitro potency against ADAM17 and in cellular assays, as well as oral bioactivity in an in vivo model of TNF-α production and a collagen-induced arthritis model (Zhang et al., 2004a). The gene discussed is ADAM17; the disease is arthritic joint disease.